MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer

What happened

MacroGenics announced positive interim Phase 2 LINNET results for lorigerlimab in advanced clear cell gynecologic cancer. Lorigerlimab showed a confirmed objective response rate of 25% and a disease control rate of 44%, with a manageable safety profile and dose optimization ongoing at 3 mg/kg every three weeks.

Confirmed

Global impact / market context

The response and disease control rates suggest lorigerlimab may help some patients whose clear cell gynecologic cancer is advanced, supporting further development. MacroGenics plans to share updated LINNET results in the first half of 2027, so investors will watch whether larger data confirm these interim findings.

Analyst inference

For a small biotech company like MacroGenics, positive mid-stage cancer data can shape expectations for future trial spending and partnership interest. The confirmed response rate, disease control rate and manageable safety profile give investors specific measures to compare against later LINNET updates due in the first half of 2027.

Analyst inference

What to watch

1. MacroGenics said dose optimization is ongoing at 3 mg/kg every three weeks, and it anticipates sharing updated LINNET results in the first half of 2027, which is a scheduled future disclosure. Confirmed
2. Watch whether MacroGenics advances lorigerlimab into a later-stage trial in clear cell gynecologic cancer; the article reports no such plan, so any decision on further development remains unconfirmed. Proposed
3. Track future LINNET updates for whether the 25% confirmed response rate and 44% disease control rate hold in more patients, since larger results would clarify the treatment's potential and support development spending. Analyst inference

Evidence

• Original source link unavailable